Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Otopeni – page 39

679 clinical trials in Otopeni, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Otopeni at a glance
679
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

679 trials in Otopeni

Open in trial search

Hepatitis D+1

Not recruiting

Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years · Healthy volunteers
  • Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
  • Sponsor:Sanofi Pasteur

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug
Countries:RomaniaRomania
  • Participants:0–17 years · Healthy volunteers
  • Sponsor:Merck Sharp & Dohme LLC

Hepatitis D+1

Not recruiting

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Hepatitis D+1

Not recruiting

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Alcohol use disorder

Not recruiting

Study on the Effects of Sunobinop on Reducing Alcohol Consumption in Patients with Moderate to Severe Alcohol Use Disorder Seeking Treatment

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sunobinop tosilate
  • Sponsor:Knoa Pharma LLC

Myasthenia gravis

Not recruiting

Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Celgene Corp.

Asthma

Not recruiting

Study on GSK5784283 for Adults Aged 18-75 with Uncontrolled Asthma

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:GSK5784283
  • Sponsor:Glaxosmithkline Research & Development Limited

Systemic scleroderma

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Crohn's disease

Not recruiting

Study of SAR441566 compared to placebo for adults with moderate to severe Crohn's disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Balinatunfib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Otopeni

What the registry says about research in the country

01 Lung Cancer Research

Investigating innovative treatments for non-squamous non-small cell lung cancer (NSCLC), with a focus on patients exhibiting specific genetic markers like c-Met overexpression. Studies are evaluating the effectiveness of targeted therapies compared to standard treatments.

  • EGFR wildtype NSCLC
  • Treatment resistance patterns
  • Targeted therapy approaches

Research aims to improve survival rates and treatment outcomes for lung cancer patients.

02 Urological Oncology

Comprehensive studies focusing on renal cell carcinoma and high-risk prostate cancer. Clinical trials are exploring combination therapies and novel treatment approaches including hormone therapy with radiation treatment.

  • Advanced kidney cancer treatments
  • Prostate cancer management
  • Combination therapy efficacy

Research centers on improving disease-free survival and treatment outcomes.

03 Skin Cancer Studies

Groundbreaking research in advanced melanoma treatment, investigating the potential of combination immunotherapy approaches. Studies are comparing various therapeutic combinations to establish optimal treatment protocols.

  • Immunotherapy combinations
  • Advanced melanoma management
  • Treatment effectiveness markers

Focus on developing more effective first-line treatments for unresectable melanoma.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.